Applicant, as named in the Orange Book

Glaxo Grp Ltd

Next listed expiry: Breo Ellipta on 11 Apr 2031. 1 products with live protection, 8 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Breo Ellipta · 3 strengths fluticasone furoate; vilanterol trifenatate	fluticasone furoate; vilanterol trifenatate	204275	11 Apr 2031	patent

Recent events

25 Oct 2026Flovent Hfa · First generic approved 3 Mar 2026
25 Oct 2026Flovent Hfa · Generic approved 3 Mar 2026
24 Oct 2026Breo Ellipta · Exclusivity expires within 90 days PED13 Nov 2026
24 Oct 2026Breo Ellipta · Exclusivity expires within 90 days PED13 Nov 2026

Products without listed protection (8)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Advair Diskus 100/50 fluticasone propionate; salmeterol xinafoate	fluticasone propionate; salmeterol xinafoate	021077	open now	no listed protection
Advair Diskus 250/50 fluticasone propionate; salmeterol xinafoate	fluticasone propionate; salmeterol xinafoate	021077	open now	no listed protection
Advair Diskus 500/50 fluticasone propionate; salmeterol xinafoate	fluticasone propionate; salmeterol xinafoate	021077	open now	no listed protection
Advair Hfa · 3 strengths fluticasone propionate; salmeterol xinafoate	fluticasone propionate; salmeterol xinafoate	021254	open now	no listed protection
Flovent Diskus 100 fluticasone propionate	fluticasone propionate	020833	open now	no listed protection
Flovent Diskus 250 fluticasone propionate	fluticasone propionate	020833	open now	no listed protection
Flovent Diskus 50 fluticasone propionate	fluticasone propionate	020833	open now	no listed protection
Flovent Hfa · 3 strengths fluticasone propionate	fluticasone propionate	021433	open now	no listed protection